MRKR – Marker Therapeutics Inc
Marker Therapeutics, Inc.MRKR
$1.86Name : Marker Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $31,012,016.00
EPSttm : -1.17
Marker Therapeutics, Inc.
$1.86
3.91%$0.07Float Short %
2.48
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.1
EPS Last/This Y
0.26
EPS This/Next Y
0.14
Price
1.86
Target Price
7.87
Analyst Recom
1
Performance Q
72.22
Relative Volume
3.34
Beta
1.44
Ticker: MRKR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-08 | MRKR | 1.44 | N/A | N/A | 0 |
| 2025-12-09 | MRKR | 1.49 | N/A | N/A | 0 |
| 2025-12-10 | MRKR | 1.465 | N/A | N/A | 0 |
| 2025-12-11 | MRKR | 1.425 | N/A | N/A | 0 |
| 2025-12-12 | MRKR | 1.455 | N/A | N/A | 0 |
| 2025-12-15 | MRKR | 1.4 | N/A | N/A | 0 |
| 2025-12-16 | MRKR | 1.29 | N/A | N/A | 0 |
| 2025-12-17 | MRKR | 1.29 | N/A | N/A | 0 |
| 2025-12-18 | MRKR | 1.27 | N/A | N/A | 0 |
| 2025-12-19 | MRKR | 1.27 | N/A | N/A | 0 |
| 2025-12-22 | MRKR | 1.42 | N/A | N/A | 0 |
| 2025-12-23 | MRKR | 1.37 | N/A | N/A | 0 |
| 2025-12-26 | MRKR | 1.44 | N/A | N/A | 0 |
| 2025-12-29 | MRKR | 1.53 | N/A | N/A | 0 |
| 2025-12-30 | MRKR | 1.48 | N/A | N/A | 0 |
| 2025-12-31 | MRKR | 1.48 | N/A | N/A | 0 |
| 2026-01-02 | MRKR | 1.54 | N/A | N/A | 0 |
| 2026-01-05 | MRKR | 1.78 | N/A | N/A | 0 |
| 2026-01-06 | MRKR | 1.86 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-08 | MRKR | 1.42 | 57.1 | - | -0.92 |
| 2025-12-09 | MRKR | 1.49 | 57.1 | - | -0.92 |
| 2025-12-10 | MRKR | 1.47 | 57.1 | - | -0.92 |
| 2025-12-11 | MRKR | 1.42 | 57.1 | - | -0.92 |
| 2025-12-12 | MRKR | 1.46 | 54.8 | - | -0.94 |
| 2025-12-15 | MRKR | 1.39 | 54.8 | - | -0.94 |
| 2025-12-16 | MRKR | 1.39 | 54.8 | - | -0.94 |
| 2025-12-17 | MRKR | 1.30 | 54.8 | - | -0.94 |
| 2025-12-18 | MRKR | 1.28 | 54.8 | - | -0.94 |
| 2025-12-19 | MRKR | 1.26 | 54.8 | - | -0.94 |
| 2025-12-22 | MRKR | 1.43 | 54.8 | - | -0.94 |
| 2025-12-23 | MRKR | 1.37 | 54.8 | - | -0.94 |
| 2025-12-26 | MRKR | 1.43 | 54.8 | - | -0.94 |
| 2025-12-29 | MRKR | 1.53 | 54.8 | - | -0.94 |
| 2025-12-30 | MRKR | 1.47 | 54.8 | - | -0.94 |
| 2025-12-31 | MRKR | 1.46 | 54.8 | - | -0.94 |
| 2026-01-02 | MRKR | 1.54 | 54.8 | - | -0.94 |
| 2026-01-05 | MRKR | 1.76 | 54.8 | - | -0.94 |
| 2026-01-06 | MRKR | 1.86 | 54.8 | - | -0.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-08 | MRKR | 0.00 | 0.40 | 2.31 |
| 2025-12-09 | MRKR | 0.00 | 0.40 | 2.31 |
| 2025-12-10 | MRKR | 0.00 | 0.40 | 1.85 |
| 2025-12-11 | MRKR | 0.00 | 0.40 | 1.85 |
| 2025-12-12 | MRKR | 0.00 | 0.40 | 1.85 |
| 2025-12-15 | MRKR | 0.00 | 0.40 | 1.73 |
| 2025-12-16 | MRKR | 0.00 | 0.40 | 1.73 |
| 2025-12-17 | MRKR | 0.00 | 0.40 | 1.73 |
| 2025-12-18 | MRKR | 0.00 | 0.40 | 1.73 |
| 2025-12-19 | MRKR | 0.00 | 0.40 | 1.73 |
| 2025-12-22 | MRKR | 0.00 | 0.40 | 1.73 |
| 2025-12-23 | MRKR | 0.00 | 0.40 | 1.73 |
| 2025-12-26 | MRKR | 0.00 | 0.40 | 2.48 |
| 2025-12-29 | MRKR | 0.00 | 0.40 | 2.48 |
| 2025-12-30 | MRKR | 0.00 | 0.40 | 2.48 |
| 2025-12-31 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-02 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-05 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-06 | MRKR | 0.00 | 0.40 | 2.48 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.12
Avg. EPS Est. Current Quarter
-0.19
Avg. EPS Est. Next Quarter
-0.22
Insider Transactions
Institutional Transactions
0.4
Beta
1.44
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
20
Growth Score
21
Sentiment Score
64
Actual DrawDown %
95.1
Max Drawdown 5-Year %
-98
Target Price
7.87
P/E
Forward P/E
PEG
P/S
6.61
P/B
1.69
P/Free Cash Flow
EPS
-1.23
Average EPS Est. Cur. Y
-0.94
EPS Next Y. (Est.)
-0.79
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-304.54
Relative Volume
3.34
Return on Equity vs Sector %
-104.8
Return on Equity vs Industry %
-89.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Marker Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 5
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
stock quote shares MRKR – Marker Therapeutics Inc Stock Price stock today
news today MRKR – Marker Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MRKR – Marker Therapeutics Inc yahoo finance google finance
stock history MRKR – Marker Therapeutics Inc invest stock market
stock prices MRKR premarket after hours
ticker MRKR fair value insiders trading